Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

The role of sphingosine 1-phosphate metabolism in bone and joint pathologies and ectopic calcification.

El Jamal A, Bougault C, Mebarek S, Magne D, Cuvillier O, Brizuela L.

Bone. 2020 Jan;130:115087. doi: 10.1016/j.bone.2019.115087. Epub 2019 Oct 21. Review.

PMID:
31648078
2.

Sphingosine kinase-1 predicts overall survival outcomes in non-small cell lung cancer patients treated with carboplatin and navelbine.

Gachechiladze M, Tichý T, Kolek V, Grygárková I, Klein J, Mgebrishvili G, Kharaishvili G, Janíková M, Smičková P, Cierna L, Pitson S, Maddelein ML, Cuvillier O, Škarda J.

Oncol Lett. 2019 Aug;18(2):1259-1266. doi: 10.3892/ol.2019.10447. Epub 2019 Jun 7.

3.

Development and characterization of sphingosine 1-phosphate receptor 1 monoclonal antibody suitable for cell imaging and biochemical studies of endogenous receptors.

Talmont F, Moulédous L, Baranger M, Gomez-Brouchet A, Zajac JM, Deffaud C, Cuvillier O, Hatzoglou A.

PLoS One. 2019 Mar 7;14(3):e0213203. doi: 10.1371/journal.pone.0213203. eCollection 2019.

4.

Pharmacomodulation on Gold-NHC complexes for anticancer applications - is lipophilicity the key point?

Zhang C, Maddelein ML, Wai-Yin Sun R, Gornitzka H, Cuvillier O, Hemmert C.

Eur J Med Chem. 2018 Sep 5;157:320-332. doi: 10.1016/j.ejmech.2018.07.070. Epub 2018 Aug 2.

PMID:
30099254
5.

Neuronal sphingosine kinase 2 subcellular localization is altered in Alzheimer's disease brain.

Dominguez G, Maddelein ML, Pucelle M, Nicaise Y, Maurage CA, Duyckaerts C, Cuvillier O, Delisle MB.

Acta Neuropathol Commun. 2018 Apr 3;6(1):25. doi: 10.1186/s40478-018-0527-z.

6.

Cationic and Neutral N-Heterocyclic Carbene Gold(I) Complexes: Cytotoxicity, NCI-60 Screening, Cellular Uptake, Inhibition of Mammalian Thioredoxin Reductase, and Reactive Oxygen Species Formation.

Zhang C, Hemmert C, Gornitzka H, Cuvillier O, Zhang M, Sun RW.

ChemMedChem. 2018 Jun 20;13(12):1218-1229. doi: 10.1002/cmdc.201800181. Epub 2018 May 23.

PMID:
29603648
7.

[Sphingosine 1-phosphate as a new regulator of mitosis].

Cuvillier O, Hatzoglou A.

Med Sci (Paris). 2018 Feb;34(2):112-114. doi: 10.1051/medsci/20183402003. Epub 2018 Feb 16. French. No abstract available.

8.

Sphingosine 1-Phosphate signaling controls mitosis.

Cuvillier O, Hatzoglou A.

Oncotarget. 2017 Nov 7;8(70):114414-114415. doi: 10.18632/oncotarget.22310. eCollection 2017 Dec 29. No abstract available.

9.

Sphingosine 1-phosphate signaling through its receptor S1P5 promotes chromosome segregation and mitotic progression.

Andrieu G, Ledoux A, Branka S, Bocquet M, Gilhodes J, Walzer T, Kasahara K, Inagaki M, Sabbadini RA, Cuvillier O, Hatzoglou A.

Sci Signal. 2017 Mar 28;10(472). pii: eaah4007. doi: 10.1126/scisignal.aah4007.

PMID:
28351953
10.

The therapeutic potential of HIF-2 antagonism in renal cell carcinoma.

Cuvillier O.

Transl Androl Urol. 2017 Feb;6(1):131-133. doi: 10.21037/tau.2017.01.12.

11.

[Erratum to "Mechanisms of castration resistance: Intratumoral hypoxia stimulates the androgen receptor expression" [Prog. Urol. 26 (3) (2016) 159-167]].

Lunardi P, Brizuela Madrid L, Beauval JB, Roumiguié M, Soulié M, Cuvillier O, Malavaud B.

Prog Urol. 2016 Jun;26(8):484. doi: 10.1016/j.purol.2016.07.001. French. No abstract available.

PMID:
27521734
12.
13.

Essential role for SphK1/S1P signaling to regulate hypoxia-inducible factor 2α expression and activity in cancer.

Bouquerel P, Gstalder C, Müller D, Laurent J, Brizuela L, Sabbadini RA, Malavaud B, Pyronnet S, Martineau Y, Ader I, Cuvillier O.

Oncogenesis. 2016 Mar 14;5:e209. doi: 10.1038/oncsis.2016.13.

14.

[Mechanisms of castration resistance: Intratumoral hypoxia stimulates the androgen receptor expression].

Lunardi P, Beauval JB, Roumiguié M, Soulié M, Cuvillier O, Malavaud B.

Prog Urol. 2016 Mar;26(3):159-67. doi: 10.1016/j.purol.2016.01.004. Epub 2016 Feb 16. French.

PMID:
26896427
15.

[SphingomabTM, an anti-sphingosine 1-phosphate antibody to inhibit hypoxia].

Cuvillier O.

Med Sci (Paris). 2015 Nov;31(11):964-7. doi: 10.1051/medsci/20153111009. Epub 2015 Nov 17. French. No abstract available.

16.

Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer.

Ader I, Gstalder C, Bouquerel P, Golzio M, Andrieu G, Zalvidea S, Richard S, Sabbadini RA, Malavaud B, Cuvillier O.

Oncotarget. 2015 May 30;6(15):13803-21.

17.

Inhibition of the GTPase Rac1 mediates the antimigratory effects of metformin in prostate cancer cells.

Dirat B, Ader I, Golzio M, Massa F, Mettouchi A, Laurent K, Larbret F, Malavaud B, Cormont M, Lemichez E, Cuvillier O, Tanti JF, Bost F.

Mol Cancer Ther. 2015 Feb;14(2):586-96. doi: 10.1158/1535-7163.MCT-14-0102. Epub 2014 Dec 19.

18.

Gem GTPase acts upstream Gmip/RhoA to regulate cortical actin remodeling and spindle positioning during early mitosis.

Andrieu G, Quaranta M, Leprince C, Cuvillier O, Hatzoglou A.

Carcinogenesis. 2014 Nov;35(11):2503-11. doi: 10.1093/carcin/bgu185. Epub 2014 Aug 30.

PMID:
25173885
19.

Synthesis, structures, and selective toxicity to cancer cells of gold(I) complexes involving N-heterocyclic carbene ligands.

Boselli L, Ader I, Carraz M, Hemmert C, Cuvillier O, Gornitzka H.

Eur J Med Chem. 2014 Oct 6;85:87-94. doi: 10.1016/j.ejmech.2014.07.086. Epub 2014 Jul 24.

PMID:
25078312
20.

Synthesis of fluorinated agonist of sphingosine-1-phosphate receptor 1.

Aliouane L, Chao S, Brizuela L, Pfund E, Cuvillier O, Jean L, Renard PY, Lequeux T.

Bioorg Med Chem. 2014 Sep 1;22(17):4955-60. doi: 10.1016/j.bmc.2014.06.038. Epub 2014 Jun 27.

PMID:
25047939
21.

[Sphingosine 1-phosphate as a biomarker for Alzheimer's disease?].

Ceccom J, Delisle MB, Cuvillier O.

Med Sci (Paris). 2014 May;30(5):493-5. doi: 10.1051/medsci/20143005006. Epub 2014 Jun 13. French. No abstract available.

22.

Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells.

Brizuela L, Martin C, Jeannot P, Ader I, Gstalder C, Andrieu G, Bocquet M, Laffosse JM, Gomez-Brouchet A, Malavaud B, Sabbadini RA, Cuvillier O.

Mol Oncol. 2014 Oct;8(7):1181-95. doi: 10.1016/j.molonc.2014.04.001. Epub 2014 Apr 13.

23.

Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer's disease.

Ceccom J, Loukh N, Lauwers-Cances V, Touriol C, Nicaise Y, Gentil C, Uro-Coste E, Pitson S, Maurage CA, Duyckaerts C, Cuvillier O, Delisle MB.

Acta Neuropathol Commun. 2014 Jan 27;2:12. doi: 10.1186/2051-5960-2-12.

24.

Hypoxia, therapeutic resistance, and sphingosine 1-phosphate.

Cuvillier O, Ader I, Bouquerel P, Brizuela L, Gstalder C, Malavaud B.

Adv Cancer Res. 2013;117:117-41. doi: 10.1016/B978-0-12-394274-6.00005-4. Review.

PMID:
23290779
25.

[Sphingosine 1-phosphate receptors: from biology to physiopathology].

Cuvillier O.

Med Sci (Paris). 2012 Nov;28(11):951-7. doi: 10.1051/medsci/20122811013. Epub 2012 Nov 12. French.

26.

First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer.

Brizuela L, Ader I, Mazerolles C, Bocquet M, Malavaud B, Cuvillier O.

Mol Cancer Ther. 2012 Sep;11(9):1841-51. doi: 10.1158/1535-7163.MCT-12-0227. Epub 2012 Jul 10.

27.

Biochemical methods for quantifying sphingolipids: ceramide, sphingosine, sphingosine kinase-1 activity, and sphingosine-1-phosphate.

Brizuela L, Cuvillier O.

Methods Mol Biol. 2012;874:1-20. doi: 10.1007/978-1-61779-800-9_1.

PMID:
22528435
28.

Inhibition of Cu-amyloid-β by using bifunctional peptides with β-sheet breaker and chelator moieties.

Jensen M, Canning A, Chiha S, Bouquerel P, Pedersen JT, Østergaard J, Cuvillier O, Sasaki I, Hureau C, Faller P.

Chemistry. 2012 Apr 16;18(16):4836-9. doi: 10.1002/chem.201103546. Epub 2012 Mar 15.

PMID:
22422637
29.

Hypoxia-inducible factors and sphingosine 1-phosphate signaling.

Cuvillier O, Ader I.

Anticancer Agents Med Chem. 2011 Nov;11(9):854-62. Review.

PMID:
21707486
30.

Production of multiple brain-like ganglioside species is dispensable for fas-induced apoptosis of lymphoid cells.

Popa I, Therville N, Carpentier S, Levade T, Cuvillier O, Portoukalian J.

PLoS One. 2011;6(5):e19974. doi: 10.1371/journal.pone.0019974. Epub 2011 May 24.

31.

Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens.

Malavaud B, Pchejetski D, Mazerolles C, de Paiva GR, Calvet C, Doumerc N, Pitson S, Rischmann P, Cuvillier O.

Eur J Cancer. 2010 Dec;46(18):3417-24. doi: 10.1016/j.ejca.2010.07.053. Epub 2010 Oct 20.

PMID:
20970322
32.

FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.

Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, Golzio M, Salunkhe V, Teissié J, Malavaud B, Waxman J, Cuvillier O.

Cancer Res. 2010 Nov 1;70(21):8651-61. doi: 10.1158/0008-5472.CAN-10-1388. Epub 2010 Oct 19.

33.

The sphingosine kinase-1 survival pathway is a molecular target for the tumor-suppressive tea and wine polyphenols in prostate cancer.

Brizuela L, Dayon A, Doumerc N, Ader I, Golzio M, Izard JC, Hara Y, Malavaud B, Cuvillier O.

FASEB J. 2010 Oct;24(10):3882-94. doi: 10.1096/fj.10-160838. Epub 2010 Jun 3.

PMID:
20522783
34.

Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting.

Cuvillier O, Ader I, Bouquerel P, Brizuela L, Malavaud B, Mazerolles C, Rischmann P.

Curr Mol Pharmacol. 2010 Jun;3(2):53-65. Review.

PMID:
20302564
35.

Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival.

Dayon A, Brizuela L, Martin C, Mazerolles C, Pirot N, Doumerc N, Nogueira L, Golzio M, Teissié J, Serre G, Rischmann P, Malavaud B, Cuvillier O.

PLoS One. 2009 Nov 26;4(11):e8048. doi: 10.1371/journal.pone.0008048.

36.

Sphingosine kinase-1 mediates androgen-induced osteoblast cell growth.

Martin C, Lafosse JM, Malavaud B, Cuvillier O.

Biochem Biophys Res Commun. 2010 Jan 1;391(1):669-73. doi: 10.1016/j.bbrc.2009.11.118. Epub 2009 Nov 20.

PMID:
19932089
37.

Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel.

Sauer L, Nunes J, Salunkhe V, Skalska L, Kohama T, Cuvillier O, Waxman J, Pchejetski D.

Int J Cancer. 2009 Dec 1;125(11):2728-36. doi: 10.1002/ijc.24640.

38.

When the sphingosine kinase 1/sphingosine 1-phosphate pathway meets hypoxia signaling: new targets for cancer therapy.

Ader I, Malavaud B, Cuvillier O.

Cancer Res. 2009 May 1;69(9):3723-6. doi: 10.1158/0008-5472.CAN-09-0389. Epub 2009 Apr 21. Review.

39.

Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug.

Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, Delisle MB, Cuvillier O, Susini C, Bousquet C.

Mol Cancer Ther. 2009 Apr;8(4):809-20. doi: 10.1158/1535-7163.MCT-08-1096.

40.

Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells.

Ader I, Brizuela L, Bouquerel P, Malavaud B, Cuvillier O.

Cancer Res. 2008 Oct 15;68(20):8635-42. doi: 10.1158/0008-5472.CAN-08-0917.

41.

Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models.

Pchejetski D, Doumerc N, Golzio M, Naymark M, Teissié J, Kohama T, Waxman J, Malavaud B, Cuvillier O.

Mol Cancer Ther. 2008 Jul;7(7):1836-45. doi: 10.1158/1535-7163.MCT-07-2322.

42.

Downregulating sphingosine kinase-1 for cancer therapy.

Cuvillier O.

Expert Opin Ther Targets. 2008 Aug;12(8):1009-20. doi: 10.1517/14728222.12.8.1009 . Review.

PMID:
18620522
43.

Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells.

Bonhoure E, Lauret A, Barnes DJ, Martin C, Malavaud B, Kohama T, Melo JV, Cuvillier O.

Leukemia. 2008 May;22(5):971-9. doi: 10.1038/leu.2008.95. Epub 2008 Apr 10.

PMID:
18401414
44.

Critical role for sphingosine kinase-1 in regulating survival of neuroblastoma cells exposed to amyloid-beta peptide.

Gomez-Brouchet A, Pchejetski D, Brizuela L, Garcia V, Altié MF, Maddelein ML, Delisle MB, Cuvillier O.

Mol Pharmacol. 2007 Aug;72(2):341-9. Epub 2007 May 23.

PMID:
17522181
45.

Sphingosine kinase-1--a potential therapeutic target in cancer.

Cuvillier O.

Anticancer Drugs. 2007 Feb;18(2):105-10. Review.

PMID:
17159597
46.

Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis.

Pchejetski D, Kunduzova O, Dayon A, Calise D, Seguelas MH, Leducq N, Seif I, Parini A, Cuvillier O.

Circ Res. 2007 Jan 5;100(1):41-9. Epub 2006 Dec 7.

PMID:
17158340
47.

Novel synergistic mechanism for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk between NF-kappaB and JNK pathways.

Guillermet-Guibert J, Saint-Laurent N, Davenne L, Rochaix P, Cuvillier O, Culler MD, Pradayrol L, Buscail L, Susini C, Bousquet C.

Cell Death Differ. 2007 Feb;14(2):197-208. Epub 2006 Apr 28.

48.

Regulation by sphingosine 1-phosphate of Bax and Bad activities during apoptosis in a MEK-dependent manner.

Betito S, Cuvillier O.

Biochem Biophys Res Commun. 2006 Feb 24;340(4):1273-7. Epub 2006 Jan 6.

PMID:
16414356
49.

Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models.

Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissié J, Malavaud B, Cuvillier O.

Cancer Res. 2005 Dec 15;65(24):11667-75.

50.

Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1.

Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, Kohama T, Cuvillier O.

Leukemia. 2006 Jan;20(1):95-102.

PMID:
16281067

Supplemental Content

Loading ...
Support Center